

Quarterly Compliance Report on Corporate Governance

Scrip Code - 512529

Name of the Company: Sequent Scientific Limited

Quarter ending on: September 30, 2015


Particulars	Clause of Listing agreement	Compliance Status Yes/ No	Remarks
II. Board of Directors	49 (II)		
(A) Composition of Board	49 (IIA)	Yes	Nil
(B) Independent Directors	49 (IIB)	Yes	Nil
(C) Non-executive Directors' compensation & disclosures	49 (IIC)	Yes	Nil
(D) Other provisions as to Board and Committees	49 (IID)	Yes	Nil
(E) Code of Conduct	49 (IIE)	Yes	Nil
(F) Whistle Blower Policy	49 (IIF)	Yes	Nil
III. Audit Committee	49 (III)		
(A) Qualified & Independent Audit Committee	49 (IIIA)	Yes	Nil
(B) Meeting of Audit Committee	49 (IIIB)	Yes	Nil
(C) Powers of Audit Committee	49 (IIIC)	Yes	Nil
(D) Role of Audit Committee	49 (IIID)	Yes	Nil
(E) Review of Information by Audit Committee	49 (IIIE)	Yes	Nil
IV. Nomination and Remuneration Committee	49 (IV)	Yes	Nil
V. Subsidiary Companies	49 (V)	Yes	Nil
VI. Risk Management	49 (VI)	Yes	Constitution of Risk Management Committee is not applicable to the Company
VII. Related Party Transactions	49(VII)	NA	Nil
Disclosures	49 (VIII)		
(A) Related party transactions	49 (VIIIA)	NA	Attached as an Annexure
(B) Disclosure of Accounting Treatment	49(VIIIB)	NA	Nil
(C) Remuneration of Directors	49 (VIII C)	Yes	Nil
(D) Management	49 (VIII D)	Yes	Nil
(E) Shareholders	49(VIII E)	Yes	Nil

SeQuent Scientific Limited

Corporate Office : Star I, Opp. IIM, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India. Tel: +91 80 6784 0340 Fax: +91 80 6784 0400

Regd. Office : 301, 3rd Floor, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W), Mumbai - 400 604, India. Tel: +91 22 4111 4777 Fax: +91 22 4111 4754


CIN : L99999MH1985PLC036685 | Email : info@sequent.in | www.sequent.in



Continuation Sheet

(F) Proceeds from public issues, rights issue, preferential issues, etc.	49(VIII I)	Yes	Nil
VIII. CEO/ CFO Certification	49 (IX)	Yes	Nil
IX. Report on Corporate Governance	49 (X)	Yes	Nil
X. Compliance	49 (XI)	Yes	Nil

Place: Bangalore
Date: October 12, 2015



For Sequent Scientific Limited

A handwritten signature in black ink, appearing to read "Preetham Hebbar".


Preetham Hebbar
Company Secretary & Compliance Officer

Continuation Sheet

Annexure

Details of material transactions with related parties:

Sl. No.	Name of the related party	Name of the Director or Key Managerial Personnel who is related, if any	Nature of relationship	Nature, material terms & particulars of the contract or arrangement from upto March 31, 2016	Monetary Value upto (Rupees in Million)	Any other information
1.	Strides Arcolab Limited, India ("Strides")	Mr. Arun Kumar, Promoter of the company is a Promoter and Managing Director of Strides	Enterprises owned or significantly influenced by Key Management Personnel (Related Party as per Accounting Standard - 18)	Sale of Material / Services as per prevailing market prices	2,000.00	The Company will supply Active Pharmaceutical Ingredients (Raw Materials) to Strides at prevailing market price
2.	Alivira Animal Health Limited, India ("Alivira")	Dr. Gopakumar G Nair an Independent Director of the Company is also an Independent Director in Alivira Dr. Kausalya Santhanam an Independent Director of the Company is also an Independent	Subsidiary of the Company	Sale of Material / Services at cost plus 5% mark-up	1,010.00	The Company will supply Active Pharmaceutical Ingredients and Intermediates to Alivira
				Loans and Advances to pay	500.00	To fulfil the funding requirements as and when need arises



Continuation Sheet

		<p>Director in Alivira</p> <p>Mr. Manish Gupta, Managing Director of the Company is also a Managing Director in Alivira</p> <p>Dr. Gautam Kumar Das, Joint Managing Director of the Company is also a Joint Managing Director in Alivira</p> <p>Mr. Kannan P R, Chief Financial Officer of the Company is also a Chief Financial Officer in Alivira</p>				
3.	Alivira Animal Health Limited, Ireland ("Alivira Ireland")	Mr. Kannan P R, Chief Financial Officer of the Company is a Director in Alivira Ireland	Subsidiary of the Company	Sale of Material / Services at cost plus 5% mark-up	1,010.00	The Company will supply Active Pharmaceutical Ingredients and Intermediates to Alivira Ireland

